1-5 of 5
Amanda Winters, MDPhD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Venetoclax Is Safe and Tolerable As Post-Transplant Maintenance Therapy for AML Patients at High Risk for Relapse

Andrew Kent, MD PhD, Daniel A. Pollyea, Amanda Winters, MDPhD, Craig T. Jordan, PhD, Clayton Smith, MD, Jonathan A. Gutman, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 11–12.
https://doi.org/10.1182/blood-2020-138832
Published: 2020
Journal Articles

Venetoclax and Azacitidine for Newly Diagnosed Non-Elderly Adult Patients with Acute Myeloid Leukemia and Adverse Risk Features

Jonathan A. Gutman, MD, Amanda Winters, MDPhD, Maria L Amaya, MD PhD, Christine M. McMahon, MD, Jeffrey Schowinsky, MD, Diana Abbott, PhD, Andrew Hammes, MS, Shanshan Pei, PhD, Brett M. Stevens, PhD, Craig T. Jordan, PhD, Clayton Smith, MD, Daniel A. Pollyea
Journal: Blood
Blood (2020) 136 (Supplement 1): 9.
https://doi.org/10.1182/blood-2020-136120
Published: 2020
Journal Articles

Allogeneic Transplant Improves AML Outcomes Compared to Maintenance Venetoclax and Azacitidine Following Response to Initial Venetoclax and Azacitidine Therapy

Daniel A. Pollyea, Amanda Winters, MDPhD, Craig T. Jordan, PhD, Clayton Smith, MD, Jonathan A. Gutman, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 24.
https://doi.org/10.1182/blood-2020-138821
Published: 2020
Journal Articles

WT1 and BCORL1 Identified By Computational Biology Modeling Analysis of Patient Genomics Are Novel Predictors of Response to Azacitidine (AZA) and Lenalidomide (LEN) Treatment in Acute Myeloid Leukemia (AML)

Brett M Stevens, PhD, Amanda Winters, MDPhD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Yashaswini S Ullal, B.E, Ilu Kumari, M.Sc., Anuj Tyagi, M.Sc., Aftab Alam, M.Sc., Neelesh Lunkad, M.Tech, Leylah M. Drusbosky, PhD, Christopher R. Cogle, MD, Shireen Vali, PhD, Daniel A Pollyea, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1538.
https://doi.org/10.1182/blood-2018-99-114429
Published: 2018
Journal Articles

PTPN11 Mutations Confer Unique Metabolic Properties and Increase Resistance to Venetoclax and Azacitidine in Acute Myelogenous Leukemia

Brett M. Stevens, PhDBS, Courtney L Jones, PhD, Amanda Winters, MDPhD, James Dugan, MD, Diana Abbott, PhD, Michael R. Savona, MD, Stephen W. Fesik, PhD, Daniel A Pollyea, MD, Craig T Jordan, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 909.
https://doi.org/10.1182/blood-2018-99-119806
Published: 2018